Eduovisual
Cardiovascular
Aortic regurgitation: chronic medical management and surgical timing
— Valve: bicuspid aortic valve (most common in young US adults), rheumatic (worldwide leader), endocarditis sequelae, calcific degeneration in elderly, anorectic drugs.
— Root/ascending aorta: hypertensive aortopathy, Marfan/Loeys-Dietz/Ehlers-Danlos, syphilitic aortitis (tertiary), giant cell or Takayasu arteritis, aortic dissection (acute but can become chronic).
— Wide pulse pressure (>50% of SBP) or "water-hammer" peripheral pulses in an asymptomatic patient.
— Incidental diastolic murmur on routine exam, especially in a tall thin patient (Marfan habitus) or known BAV.
— Young athlete with progressive exercise intolerance + bounding pulses.
— Echo done for another reason showing dilated LV with preserved EF and AR jet.
Board pearl: A wide pulse pressure with bounding pulses in an asymptomatic adult should trigger a TTE — chronic AR is the classic "silent" valvular lesion with years of subclinical LV remodeling before symptoms emerge, and early detection drives the surgical timing decision that defines this topic.
— Palpitations, "pounding" sensation in chest or head, especially when supine.
— Sinus tachycardia or PVCs poorly tolerated.
— Neck pulsations the patient notices in the mirror.
— Exertional dyspnea — earliest sign of rising LVEDP.
— Orthopnea, PND, frank pulmonary edema (late).
— Angina, often nocturnal, from low diastolic coronary perfusion pressure + LVH increasing O2 demand, even with normal coronaries.
— Syncope is uncommon in chronic AR (unlike AS) — if present, think arrhythmia or coexisting disease.
— Prior rheumatic fever, IVDU, recent dental/GU procedure (endocarditis).
— Family history of aortic aneurysm, sudden death, or connective tissue disease.
— Known BAV — ask about surveillance echo frequency.
— Hypertension control (poorly controlled HTN accelerates root dilation).
— Anorectic/ergot drug exposure historically.
— Functional status trajectory: subtle declines in exercise tolerance over months matter more than a single snapshot.
Step 3 management: When a previously asymptomatic chronic AR patient reports new exertional dyspnea or declining exercise tolerance, do not wait for the next scheduled echo — order a TTE now and refer to cardiology for surgical evaluation, because symptom onset is itself a Class I indication for aortic valve replacement regardless of LV size or EF. Symptom history is the single highest-yield data point in this topic.
— High-pitched, decrescendo diastolic murmur at left sternal border (valvular AR) or right sternal border (aortic root dilation — "Harvey's sign").
— Best heard with patient leaning forward, breath held in expiration, diaphragm.
— Austin Flint murmur: mid-to-late diastolic rumble at apex from AR jet impinging on anterior mitral leaflet — mimics MS but no opening snap.
— Soft S1 (premature mitral closure); S3 with LV dysfunction.
— Systolic ejection murmur often present from increased stroke volume (functional, not AS).
— Corrigan/water-hammer pulse — rapid upstroke, quick collapse.
— de Musset sign — head bobbing with each beat.
— Müller sign — uvular pulsation.
— Quincke sign — capillary pulsations in nailbed.
— Traube sign — "pistol-shot" femoral sounds.
— Duroziez sign — to-and-fro femoral bruit with light compression.
— Hill sign — popliteal SBP exceeds brachial by >60 mm Hg.
Key distinction: Acute severe AR (endocarditis, dissection) presents very differently — narrow pulse pressure, soft/absent murmur, tachycardia, pulmonary edema, and cardiogenic shock because the non-dilated LV cannot accommodate sudden regurgitant volume. Acute AR is a surgical emergency; chronic AR is a longitudinal outpatient timing problem. Confusing the two is a classic Step 3 trap — exam findings of "warm, wide pulse pressure, well-appearing" point chronic; "cold, narrow pulse pressure, crashing" points acute.
— Confirms AR, quantifies severity, measures LV end-systolic dimension (LVESD) and LV end-diastolic dimension (LVEDD), LVEF, and aortic root/ascending aorta dimensions.
— Severity graded by vena contracta width (>0.6 cm severe), regurgitant volume (>60 mL/beat severe), regurgitant fraction (>50% severe), pressure half-time (<200 ms severe), and holodiastolic flow reversal in descending aorta.
— LV hypertrophy with volume-overload pattern (tall R in V5/V6, deep S in V1/V2, prominent Q waves laterally).
— Left axis deviation.
— Eventual T-wave inversions in lateral leads ("LV strain") signal decompensation.
— Cardiomegaly with apex displaced inferolaterally ("boot-shaped").
— Dilated ascending aorta or aortic knob.
— Pulmonary congestion only if decompensated.
CCS pearl: On a CCS case of suspected chronic AR, the efficient opening sequence is vitals → focused cardiac exam → ECG → CXR → TTE → BNP. Avoid ordering cardiac catheterization or TEE first — they are downstream studies. Document NYHA class and blood pressure at every clinic visit because these data points trigger the next branch point in the algorithm (medical optimization vs surgical referral). Always quantify AR severity on echo before making any management decision; mild–moderate AR with normal LV does not require vasodilator therapy or frequent imaging.
— Indicated when TTE images are inadequate, when endocarditis is suspected (vegetations, perivalvular abscess), or for preoperative anatomic detail.
— Better delineates leaflet morphology (BAV phenotype, perforation, prolapse) and root anatomy.
— Gold standard for quantifying regurgitant volume and fraction when echo is discordant or technically limited.
— Also quantifies LV volumes and EF more reproducibly than echo — useful in serial assessment of borderline cases.
— Regurgitant fraction >33% by CMR predicts need for surgery and adverse outcomes.
— Indicated when ascending aorta is dilated on TTE or in any patient with BAV, Marfan, or known aortopathy.
— Provides accurate root and ascending aorta diameters guiding the surgical threshold (generally ≥5.5 cm, or ≥5.0 cm with BAV plus risk features, Marfan, or family history of dissection).
— Useful in patients reporting equivocal symptoms or sedentary lifestyles to objectively document functional capacity and BP response.
— Drop in BP or limited exercise tolerance argues for surgical referral even with "asymptomatic" history.
— Preoperative in men >40 and postmenopausal women, or any patient with CAD risk factors, prior to AVR — to identify concomitant CABG needs.
— Aortography rarely needed now that echo/CMR are robust.
Board pearl: Discordance between echo severity and clinical picture (e.g., "moderate" AR but progressive LV dilation, or symptoms out of proportion) is the cue to obtain CMR for definitive quantification. Don't let an underestimated echo grade defer a needed surgical referral; CMR-quantified regurgitant fraction often reclassifies disease and clarifies timing.
— Symptomatic severe AR, regardless of LVEF.
— Asymptomatic severe AR with LVEF ≤55% (recent guidelines lowered from ≤50%).
— Severe AR in a patient undergoing other cardiac surgery (CABG, other valve).
— Asymptomatic severe AR with LVESD >50 mm (or >25 mm/m² indexed) — progressive LV dilation predicts irreversible dysfunction.
— Severe AR with progressive decline in LVEF to low-normal range or progressive LV dilation on serial imaging.
— Asymptomatic severe AR with LVEDD >65 mm if surgical risk is low.
— ≥5.5 cm in general population.
— ≥5.0 cm with BAV plus risk features (family history dissection, rapid growth ≥0.5 cm/yr, coarctation).
— ≥5.0 cm in Marfan; ≥4.5 cm in Loeys-Dietz or with high-risk features.
Step 3 management: Memorize the trigger trio — symptoms, EF ≤55%, LVESD >50 mm — for surgical referral in chronic severe AR. Any one of these in a patient with severe AR mandates referral to cardiothoracic surgery. Asymptomatic patients meeting none of these get serial TTE every 6–12 months depending on LV trajectory, and aggressive blood pressure control with goal SBP <130.
— Target SBP <130 mm Hg.
— Preferred agents: dihydropyridine CCBs (amlodipine, nifedipine), ACE inhibitors, ARBs — all reduce afterload and wall stress.
— Avoid agents that markedly lower heart rate (non-DHP CCBs, high-dose beta-blockers in isolation) because bradycardia prolongs diastole and worsens regurgitant volume.
— Symptomatic severe AR but patient is not a surgical candidate.
— Severe AR with hypertension.
— Persistent LV dysfunction after AVR.
— Not indicated routinely in asymptomatic patients with normal LV and normal BP.
— Marfan/aortopathy — slow root dilation (often combined with ARB; losartan has aortopathy-modifying data in Marfan).
— Coexisting CAD, atrial fibrillation, or post-AVR.
Board pearl: A common Step 3 distractor: starting vasodilators in asymptomatic mild–moderate AR with normal BP. Don't — there's no mortality benefit, and it may delay needed surgical referral by giving false reassurance. Treat hypertension if present; otherwise, surveillance and risk-factor control only.
— Mechanical valve: durable, requires lifelong warfarin (INR 2.0–3.0 for aortic position), preferred in patients <50–60 years without bleeding risk.
— Bioprosthetic valve: no chronic anticoagulation, but ~10–15 year durability; preferred in patients >65–70 years, women planning pregnancy, bleeding risk, poor anticoagulation compliance.
— Shared decision-making between 50–65 years.
— Increasingly performed in young patients with BAV and selected tricuspid AR with suitable leaflet anatomy.
— Avoids anticoagulation and prosthesis-related complications.
— Often combined with aortic root replacement (valve-sparing root replacement — David or Yacoub procedure) in aortopathy patients with preserved leaflets.
— Off-label and limited in pure native AR — most TAVR devices designed for stenotic, calcified annuli; AR annuli are often non-calcified and dilated, leading to migration/paravalvular leak.
— Reserved for high or prohibitive surgical risk patients at experienced centers; newer dedicated devices emerging.
— Coronary angiography preoperatively if CAD risk factors.
— Optimize HF, treat infection, dental clearance for prosthetic valves.
Step 3 management: When asked which valve to choose in a 45-year-old man with severe AR and BAV, the answer is typically mechanical valve (or valve-sparing repair if anatomy permits) — durability matters more than avoiding warfarin in younger patients. For a 72-year-old, bioprosthetic is preferred. Always factor in pregnancy planning, bleeding risk, and patient preference into shared decision-making.
— Calcific degeneration becomes the leading etiology; often combined AS/AR.
— Higher surgical risk from frailty, CAD, COPD, prior strokes — use STS risk score and a multidisciplinary Heart Team evaluation.
— Bioprosthetic valves preferred — durability less of a concern given life expectancy, and anticoagulation risk is higher.
— Symptoms may be masked by sedentary lifestyle; objective testing (stress test, BNP, serial echo) more important.
— Consider TAVR only in prohibitive-risk pure AR at experienced centers; otherwise SAVR remains standard.
— CKD accelerates valvular calcification and worsens postoperative outcomes.
— Optimize volume status; avoid nephrotoxic contrast — use minimal-contrast CT or CMR when possible for preoperative imaging.
— Adjust ACEi/ARB cautiously; monitor potassium and creatinine.
— Avoid NSAIDs which both impair renal function and worsen hypertension.
— Dialysis patients: timing of valve surgery requires close coordination with nephrology; mechanical valves problematic due to bleeding risk on dialysis.
— Cirrhotic patients have markedly elevated surgical mortality — Child-Pugh and MELD scores predict outcomes.
— Warfarin management complicated by baseline INR elevation — favors bioprosthetic valves.
— Coagulopathy and thrombocytopenia raise perioperative bleeding risk; coordinate with hepatology preoperatively.
Key distinction: In elderly patients with severe AR, the question is rarely whether to operate (symptoms or EF ≤55% still trigger surgery) but how — Heart Team evaluation, frailty assessment (gait speed, grip strength), and valve type selection. Don't deny surgery based on age alone; deny based on functional status, life expectancy, and patient goals of care. A vigorous 80-year-old benefits; a frail 65-year-old with dementia may not.
— Usually well-tolerated because physiologic decreases in SVR and tachycardia of pregnancy reduce regurgitant fraction.
— Preconception counseling: assess LV function, AR severity, aortic root size, and functional class.
— mWHO classification stratifies maternal cardiac risk; severe AR with symptoms or LV dysfunction is mWHO III–IV.
— Avoid ACEi/ARBs (teratogenic — renal dysgenesis, oligohydramnios); switch to hydralazine, labetalol, methyldopa, nifedipine.
— Warfarin teratogenic 1st trimester — transition to LMWH if mechanical valve in place.
— Delivery: vaginal preferred with assisted second stage; cesarean for obstetric indications.
— FBN1 mutation, autosomal dominant.
— Root dilation drives surgical timing — replace ascending aorta at ≥5.0 cm (or ≥4.5 cm with family history of dissection or rapid growth).
— Pregnancy contraindicated if root >4.5 cm; counsel on dissection risk.
— Beta-blockers + losartan slow root dilation.
— Lifestyle: avoid isometric/contact sports.
Board pearl: A pregnant patient with known Marfan and aortic root 4.5 cm is a high-risk obstetric case requiring multidisciplinary care (cardiology, MFM, anesthesia, CT surgery) and serial echos every trimester. Counsel her preconception that root >4.5 cm is a relative contraindication to pregnancy due to dissection risk that rises in 3rd trimester and peripartum.
— Eccentric hypertrophy initially compensates; chronic wall stress eventually causes myocyte loss, fibrosis, and systolic dysfunction.
— Once LVEF drops below 50%, recovery after AVR is incomplete in many patients — emphasizing early surgical timing.
— Initially diastolic, progressing to systolic.
— Pulmonary edema, orthopnea, reduced exercise tolerance.
— Cardiogenic shock in acute decompensation or superimposed acute AR.
— Atrial fibrillation from LA dilation — worsens hemodynamics due to loss of atrial kick and rate dependence on diastolic filling.
— Ventricular arrhythmias in advanced disease — sudden cardiac death risk rises with LV dilation and dysfunction.
— Low diastolic aortic pressure reduces coronary perfusion.
— LVH increases O2 demand.
— Nocturnal angina classic — bradycardia + supine prolong diastole and worsen regurgitation.
— Native AR valves are at moderate risk; symptoms include new murmur, fever, embolic phenomena.
— Endocarditis can precipitate acute on chronic AR with hemodynamic collapse.
— Particularly in BAV, Marfan, and other aortopathies — type A dissection is a surgical emergency presenting with tearing chest/back pain, pulse deficits, new AR murmur.
— Persistent LV dysfunction, prosthetic valve thrombosis, paravalvular leak, structural valve deterioration (bioprosthetic), thromboembolism, endocarditis, bleeding from anticoagulation.
CCS pearl: A patient with known chronic AR presenting with acute tearing chest pain, new wide pulse pressure differential between arms, and worsening diastolic murmur — order CT angiography of chest/abdomen/pelvis STAT, start esmolol to target HR <60 and SBP <120, hold vasodilators alone until rate controlled, and call cardiothoracic surgery emergently. Type A dissection with AR has 1%/hr mortality untreated.
— Asymptomatic mild–moderate AR with normal LV — annual primary care visit, echo every 3–5 years (mild) or 1–2 years (moderate).
— Asymptomatic severe AR with normal LV (EF >55%, LVESD ≤50 mm) — cardiology follow-up every 6–12 months with serial TTE.
— Stable on medical therapy with controlled BP.
— New severe AR diagnosis on echo.
— Any symptom development (dyspnea, angina, palpitations) in known AR.
— LV dilation progression or EF decline on serial imaging.
— BAV or aortopathy diagnosis for surveillance plan.
— Meets Class I or IIa surgical indication (symptoms, EF ≤55%, LVESD >50 mm, ascending aorta at threshold).
— Plan AVR within 3–6 months absent contraindications.
— New or worsening heart failure not responsive to outpatient adjustment.
— Suspected endocarditis (admit for blood cultures × 3, IV antibiotics, TEE).
— Syncope or sustained arrhythmia.
— Acute AR (dissection, endocarditis, trauma) — always inpatient/ICU.
— Cardiogenic shock or pulmonary edema requiring vasoactive support.
— Acute severe AR awaiting emergent surgery — IV vasodilators (nitroprusside) and inotropes (dobutamine) to reduce afterload and augment forward flow; avoid IABP (worsens AR) and avoid pure beta-blockade in isolation (bradycardia worsens AR — unless treating dissection where rate control is mandatory and then paired with vasodilator).
Step 3 management: A patient with chronic severe AR who presents with new-onset atrial fibrillation and acute pulmonary edema should be admitted, rate-controlled cautiously, diuresed, anticoagulated per CHA₂DS₂-VASc, and have expedited surgical evaluation — atrial fibrillation often signals decompensation and tips the timing toward surgery even if prior imaging didn't quite meet thresholds.
— Also a high-pitched decrescendo diastolic murmur at left sternal border.
— Increases with inspiration (Carvallo sign) — AR does not.
— Usually from pulmonary hypertension (Graham Steell murmur) or post-tetralogy of Fallot repair.
— No peripheral signs of wide pulse pressure.
— Low-pitched diastolic rumble at apex with opening snap following loud S1.
— Best heard in left lateral decubitus with bell.
— Distinguishes from Austin Flint murmur of AR (no opening snap, no loud S1, presence of AR murmur at LSB).
— Crescendo-decrescendo systolic murmur at RUSB radiating to carotids.
— Mixed AS/AR common in calcific or rheumatic disease — pulse pressure narrows as AS dominates.
— Echo readily quantifies both lesions; thresholds for intervention differ.
— Holosystolic, not diastolic, but coexists with AR in rheumatic and connective tissue disease; LV volume overload from both compounds.
— Often causes mixed AS/AR plus aortopathy; ejection click at apex; family screening recommended (1st-degree relatives — TTE).
Key distinction: Austin Flint murmur vs MS — both apical diastolic rumbles. Austin Flint has no opening snap, no loud S1, and is accompanied by the decrescendo AR murmur at LSB; it disappears with amyl nitrite (afterload reduction reduces AR). MS has opening snap, loud S1, often atrial fibrillation, and is unchanged or louder with amyl nitrite. Echo is definitive but the bedside distinction is classic exam material.
— Thyrotoxicosis — tachycardia, tremor, weight loss; TSH suppressed; can produce bounding pulses, hyperdynamic precordium, even systolic flow murmur.
— Severe anemia — bounding pulses, flow murmurs, fatigue; CBC clarifies.
— Beriberi (wet) — thiamine deficiency, high-output HF, peripheral edema; alcoholism, bariatric surgery history.
— Paget disease of bone — AV shunting through hypervascular bone; elevated alkaline phosphatase.
— Pregnancy — physiologic increase in stroke volume.
— Large AV fistula (hemodialysis, traumatic) — local bruit, branham sign.
— Continuous "machinery" murmur at left infraclavicular area — not purely diastolic.
— Wide pulse pressure mimics AR; echo confirms.
— Wide pulse pressure in upper extremities; hypertension in arms with diminished femoral pulses and radio-femoral delay.
— Often coexists with BAV — always check femoral pulses in BAV patient.
Board pearl: Wide pulse pressure + diastolic murmur = AR until proven otherwise. Wide pulse pressure without a diastolic murmur — think isolated systolic hypertension (elderly), high-output state (anemia, hyperthyroidism, beriberi), or continuous-murmur lesion (PDA). Check TSH, CBC, and femoral pulses on every initial AR workup to rule out mimics.
— Blood pressure control to <130/80 — single most important modifiable factor for slowing progression and aortic dilation.
— Statin therapy per ASCVD risk; not specifically indicated for AR but for overall CV risk.
— Smoking cessation — strongly counseled; smoking accelerates aortopathy.
— Lipid and glycemic control per ACC/ADA guidelines.
— Avoid heavy isometric exercise (weightlifting, wrestling) in severe AR or aortopathy; aerobic activity generally encouraged.
— Lifelong warfarin with INR 2.0–3.0 (mechanical aortic, no risk factors) or 2.5–3.5 (mechanical aortic with AF, prior thromboembolism, hypercoagulable state, LV dysfunction).
— Add low-dose aspirin (75–100 mg) in selected patients with vascular disease.
— DOACs contraindicated with mechanical valves.
— Aspirin 75–100 mg daily indefinitely.
— Warfarin × 3–6 months post-op (Class IIa) in some patients; transition to aspirin alone thereafter.
— Plan for valve deterioration: serial TTE annually after 5 years.
Step 3 management: A 55-year-old man receives a mechanical AVR for severe AR. Discharge with warfarin (INR 2.0–3.0), low-dose aspirin, beta-blocker, ACE inhibitor for BP, dental prophylaxis education, and cardiology follow-up at 4–6 weeks with TTE at 6 weeks and annually thereafter. Educate patient on warfarin diet, INR monitoring, bleeding precautions, and signs of valve dysfunction (new dyspnea, embolic events, fever).
— Mild AR, normal LV: TTE every 3–5 years; clinical visit annually.
— Moderate AR, normal LV: TTE every 1–2 years.
— Severe AR, normal LV and LV size: TTE every 6–12 months; clinical visit every 6 months.
— Severe AR with LV dilation approaching thresholds: TTE every 3–6 months.
— Coexisting aortopathy: CT/MRI of aorta every 6–12 months until stable.
— NYHA functional class — ask about specific activities (stairs, blocks walked).
— Blood pressure — target <130/80.
— Murmur intensity and peripheral signs.
— Weight, volume status.
— Medication adherence and side effects.
— LVEF, LVESD, LVEDD, AR severity quantification, aortic root and ascending aorta diameter.
— Compare to prior studies — trajectory matters more than single snapshot.
— Report new dyspnea, chest pain, syncope, palpitations, fever immediately.
— Lifestyle: aerobic exercise OK in mild–moderate; restrict competitive/isometric in severe.
— Pregnancy planning — preconception counseling in young women.
— Dental hygiene to reduce endocarditis risk.
— Genetic counseling and family screening if BAV, Marfan, or familial aortopathy.
CCS pearl: In a CCS clinic case, after diagnosing severe asymptomatic AR with normal LV, schedule next echo in 6 months, cardiology follow-up in 3 months, optimize BP with amlodipine or losartan, counsel on symptom recognition, and document NYHA class. Don't refer to surgery yet, but flag the case mentally so symptoms or imaging deterioration triggers urgent referral on the next encounter.
— Shared decision-making about mechanical vs bioprosthetic valve is essential — lifelong anticoagulation vs reoperation risk, both lifetime tradeoffs.
— Document patient values: pregnancy plans, occupation (bleeding risk), reliability of INR monitoring access, geographic access to anticoagulation clinics.
— In patients aged 50–65, no clear superior choice — patient preference and goals govern; document the conversation thoroughly.
— Patients with severe AR and acute decompensation may have hypoxic delirium impairing decisional capacity — assess capacity for each specific decision (surgery, code status); involve surrogate per state law if lacking.
— Cognitively intact patients may refuse surgery even when life-saving — respect autonomy after confirming understanding of mortality risk without intervention; offer palliative-focused medical management.
— Anticoagulation handoff post-AVR is a high-risk transition — ensure clear documentation of target INR, bridging plan, follow-up appointment, lab access, and patient education.
— Discharge medication reconciliation: confirm BP meds adjusted, beta-blocker continued, NSAIDs avoided, GLP-1/SGLT2 reconciled if diabetic.
— Communicate with PCP regarding surveillance schedule and red-flag symptoms.
— Avoid NSAIDs (BP elevation, renal injury, bleeding on anticoagulation).
— Avoid gentamicin/aminoglycosides post-AVR unless necessary (nephrotoxicity in cardiac surgery population).
— Endocarditis prevention education for prosthetic valves.
— Falls assessment in elderly on warfarin — risk of intracranial hemorrhage.
— Report commercial driver license holders to state DMV if syncope or significant arrhythmia (state-dependent).
— Genetic disclosure obligations to at-risk family members in Marfan/BAV — counsel patient; clinicians do not directly notify relatives without consent.
Board pearl: A 28-year-old woman with severe AR and BAV is planning pregnancy and asks for a mechanical valve. Counsel her on warfarin teratogenicity in 1st trimester (transition to LMWH), increased thromboembolic risk in pregnancy, and consider bioprosthetic or valve-sparing repair despite shorter durability — shared decision-making prioritizing her reproductive goals is the ethically appropriate Step 3 answer.
Key distinction: Chronic AR = wide pulse pressure, slow progression, surgical timing question. Acute AR = narrow pulse pressure, shock, emergent surgery. This dichotomy alone resolves many board stems.
— Stem: "55-year-old man with known BAV, severe AR on echo (regurgitant fraction 55%), LVEF 50%, LVESD 52 mm. Asymptomatic, BP 128/60. What is next best step?"
— Answer: Refer for AVR — meets Class I (EF ≤55%) and Class IIa (LVESD >50 mm). Don't be fooled by "asymptomatic."
— Stem: "Patient with known moderate-severe AR develops exertional dyspnea over 3 months. LVEF 60%."
— Answer: Refer for AVR — symptoms alone, regardless of EF, are Class I.
— Stem: "Apical diastolic rumble, soft S1, no opening snap, decrescendo diastolic murmur at LSB."
— Answer: Austin Flint murmur of AR, not MS.
— Stem: "IV drug user with fever, narrow pulse pressure, pulmonary edema, soft diastolic murmur."
— Answer: Acute AR from endocarditis — TEE, blood cultures, IV antibiotics, emergent surgery.
— Stem: "BAV patient, mild AR, ascending aorta 5.2 cm, family history of dissection."
— Answer: Aortic replacement at ≥5.0 cm given high-risk feature.
— Stem: "Asymptomatic mild AR, BP 118/72, normal LV."
— Answer: No vasodilator therapy — observation only. Adding ACEi without indication is wrong.
— Stem: "Marfan, root 4.8 cm, planning pregnancy."
— Answer: Defer pregnancy, root replacement first (relative contraindication at >4.5 cm).
— Stem: "32-year-old needs AVR for severe AR."
— Answer: Mechanical valve or valve-sparing repair — durability priority.
— Stem: "Patient with mechanical AVR asks about DOAC for convenience."
— Answer: No — warfarin only; DOACs contraindicated.
— Stem: "Asymptomatic severe AR, normal LV."
— Answer: TTE every 6–12 months.
Step 3 management: Recognize that Step 3 stems frequently pivot on what to do next in clinic, not just diagnosis — so commit the surgical trigger trio, valve-choice age cutoffs, and surveillance intervals to memory; they recur across stems.
Chronic aortic regurgitation is a slowly progressive volume-overload lesion in which surgical timing — driven by symptom onset, LVEF ≤55%, LVESD >50 mm, or aortopathy thresholds — defines outcomes, while medical therapy (BP control with vasodilators) is supportive but never curative.
Board pearl: If you remember only one thing from this topic, remember that chronic AR is a timing problem, not a treatment problem — the question is always when to send to surgery, and the answer is at the first sign of symptoms, EF decline to ≤55%, LVESD exceeding 50 mm, or aortic dilation reaching threshold — never later.